Intellia Therapeutics, Inc. (NTLA) Stock Price & Analysis

Intellia Therapeutics, Inc. (NTLA) rose 0.47% to USD 12.74 as of September 8, 2026 at 03:32 UTC, according to Nexqual real-time market data.

NTLA last closed at USD 12.74; the session ranged USD 12.52–12.96 on volume of 2,796,288 shares. Market capitalization is —, with a 52-week range of USD 7.95–28.25 (NGM). Source: Nexqual, September 8, 2026 at 03:32 UTC.

Key Statistics (as of September 8, 2026 at 03:32 UTC)

Technical Analysis (NTLA)

Nexqual's technical model rates NTLA "BUY" based on 4 bullish and 1 bearish signals across 128 daily candles, as of September 8, 2026 at 03:32 UTC.

From Intellia Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• We aim to remain a pioneer in the field by developing additional product candidates that leverage our proprietary technologies acquired or developed over a decade-plus of research and development, including multi-modal CRISPR gene editing, LNP, and oligonucleotide technologies. 6   Collaborate with partners to expand the reach of our technology and maximize our return on investment.
• The potential application of our proprietary technologies, including CRISPR gene editing, is extremely broad, and we plan to continue to identify partners who can contribute meaningful resources and insights to our programs and allow us to more rapidly bring scientific innovation to a broader patient population.
• Our Pipeline The following table summarizes the status of our research and development programs: Lead Programs We are the first company to advance in vivo genome editing product candidates into Phase 3 development.
• Collaborations and Other Arrangements To accelerate the development and commercialization of therapeutic products that use our proprietary technologies in multiple therapeutic areas, we have formed, and intend to seek other opportunities to form, strategic alliances with collaborators who can augment our leadership in the development of therapeutic products.

Partnerships

• Strategy Our strategy is to (1) advance the clinical development of our lead CRISPR-based product candidates, (2) build and leverage a fully integrated commercial-stage infrastructure, (3) expand our pipeline utilizing our expertise and proprietary technologies, and (4) collaborate with partners to expand our technology reach and maximize our return on investment.
• Regeneron Pharmaceuticals, Inc. ("Regeneron") In April 2016, we entered into a license and collaboration agreement with Regeneron (as amended from time to time, the "2016 Regeneron Agreement").

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 03:32 UTC. This page is informational and not investment advice.